Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry (Q35219654)

7 August 2017

title

Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry (English)

1 reference

7 August 2017

1 reference

5

1 reference

7 August 2017

author name string

Mariana Rodrigues Botton

1

1 reference

7 August 2017

Eliane Bandinelli

2

1 reference

7 August 2017

Luis Eduardo Paim Rohde

3

1 reference

7 August 2017

Luis Carlos Amon

4

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

British Journal of Clinical Pharmacology

7 August 2017

published in

1 reference

7 August 2017

volume

72

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

442-450

1 reference

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

The largest prospective warfarin-treated cohort supports genetic forecasting

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

CYP4F2 genetic variant alters required warfarin dose

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

A tutorial on statistical methods for population association studies

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

CYP2C9 allelic variants: ethnic distribution and functional significance

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

An E-M algorithm and testing strategy for multiple-locus haplotypes

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Interindividual variability in sensitivity to warfarin--Nature or nurture?

13 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Probable warfarin-simvastatin interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.03942.X

Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3175513

Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin

26 September 2018

1 reference

12 December 2020

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

1 reference

12 December 2020

Genetic modulation of oral anticoagulation with warfarin

1 reference

12 December 2020

Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients

1 reference

12 December 2020

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

1 reference

12 December 2020

10.1111/J.1365-2125.2011.03942.X

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference